Introduction
Multiple myeloma (MM) is a malignant hematological disorder that accounts for approximately 1% of all cancer-related deaths in Western countries. 1 Even though advanced chemotherapeutic regimens, such as high-dose chemotherapy and autologous blood stem cell transplantation, have increased the median time of survival to 4-5 years, MM remains incurable. 2 The disease is characterized by an accumulation of plasma cells in the bone marrow (BM) leading to impaired hematopoiesis and to osteolytic bone destruction. The BM microenvironment is thought to provide essential support for the propagation and expansion of the malignant clone. 3 Specifically, it has been shown that survival, growth and drug sensitivity of MM cells are affected by their interaction with BM stromal cells (BMSCs), which constitute a major cellular compartment of the BM. 4, 5 The interplay between MM cells and BMSCs sustains cell adhesion-mediated drug resistance and induces increased levels of growth-promoting chemokines and cytokines. 6, 7 Of the latter, interleukin-6 (IL-6), which is known to be required for the terminal differentiation of B-cells, is presumed to play a major role in the pathogenesis and malignant growth of multiple myeloma. 8, 9 Stimulation of cells by IL-6 requires signaling through the IL-6 receptor (IL-6R), which consists of two subunits: IL-6R and IL-6R , which is the signal transducing chain. 10 Binding of IL-6 to IL-6R induces recruitment of IL-6R subunits and initiates at least two intracellular signaling pathways: the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3), and the Ras/Mitogenactivated protein kinase (MAPK) pathway. 11 IL-6-mediated induction of the Ras/MAPK pathway has been reported to correlate with the proliferation characteristics of IL-6-dependent MM cells. [12] [13] [14] However, data on the precise role of the MAP kinases ERK1,2 for the propagation of MM cells remains sketchy and consequently it is still unclear if the MEK1,2/ERK1,2 module represents a reasonable target for therapeutic intervention. STAT3, on the other hand, was found to be constitutively phosphorylated in a high proportion of primary myeloma samples, 15, 16 and it has been demonstrated that inhibition of the IL-6R/STAT3
pathway with IL-6R antagonists, 17 JAK-inhibitors 18 or dominant negative STAT3 expression constructs 15 induces apoptosis of human myeloma cell lines in vitro.
only.
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These experiments highlighted the potential importance of this pathway for antiapoptotic signaling in myeloma cells and identified it as an interesting target for the development of therapeutic strategies against MM. The upshot of both these pathway analyses is to implicate IL-6R/STAT3 signaling primarily with survival, and the IL-6R/MAPK-pathway with proliferation of MM cells. However, most data concerning the role of these IL-6-triggered pathways were gleaned from experiments with cell lines, and without consideration of the BM microenvironment. Therefore, the function and biological significance of these pathways, and their potential for therapeutic interference, are still unclear. Recently, we have shown that inhibition of the IL-6R/STAT3 pathway in the IL-6-dependent MM cell line INA-6 is correlated with induction of apoptosis in the absence of BMSCs, whereas no or only minor effects on either growth or survival were observed in the presence of BMSCs. 19 These observations indicate that IL-6R/STAT3 signaling is dispensable within the context of the BM microenvironment, which might stimulate IL-6-independent pathways that protect MM cells from apoptosis. We found that activation of ERK1,2 in INA-6 cells was only slightly enhanced by IL-6, but strongly induced by BMSCs. Furthermore, treatment with the farnesyl transferase inhibitor FPT III, which disrupts Ras signaling, provoked a strong apoptotic response even under coculture conditions. 19 We therefore speculated that BMSC-induced ERK activity might compensate for the lack of IL-6R/STAT3-mediated anti-apoptotic signals. In this study, we analyzed whether selective blockade of the MEK1,2/ERK1,2 module, rather than disruption of the IL-6R/STAT3 pathway, constitutes an effective means to induce apoptosis of MM cells if these are cultured in the presence of BMSCs.
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Materials and Methods

Cell culture
The human IL-6-dependent MM cell lines INA-6 20 and ANBL-6 21 were maintained in RPMI 1640, supplemented with either 20% or 10% FCS (both from Biochrom, Berlin, Germany), 100 U/mL penicillin, 100 µg/mL streptomycin (both from PAN Biotech, Aidenbach, Germany), 2 mM glutamine, 1 mM Na-pyruvate (both from Gibco, Karlsruhe, Germany), and 2 ng/mL recombinant IL-6. For cell culture of primary cells, see ref. 19 All cells were grown at 37°C and 5% CO 2 .
Electroporation of INA-6 cells
INA-6 cells at densities of 4x10 µg/mL for pCD4 , and 10 µg/mL for pSUPER constructs. 500 µL of cell suspension was used per electroporation. Electroporated cells were mixed with an equal volume of medium without additives, kept at 37°C until all samples were addressed, and then transferred to prewarmed full medium with IL-6 to recover overnight. 
Purification of electroporated INA-6 cells
Construction of siRNA expression vectors
PSUPER-derived expression vectors for siRNAs against ERK1, ERK2 and STAT3,
were designed according to guidelines in ref. 22 Efficacy of the constructs was tested clone. In order to introduce an HA-tag, the first 470 bases of this clone were exchanged for the equivalent but HA-tagged murine sequence (a kind gift from Prof.
Hamaguchi, Nagoya University, Japan) via the common XbaI site, and the chimeric STAT3 gene was cloned into the expression vector pCAGGS. This plasmid was used at a concentration of 10 µg/mL in electroporations. 
Western blot analysis
Myeloma cells cocultured with BMSCs were washed off to avoid contamination with stromal cells. Otherwise, all procedures followed those detailed in ref. 19 , except that an anti--tubulin antibody was employed to assess equal loading.
Reagents
The following antibodies were used: anti-ERK1/2 (#442675, Calbiochem, only.
Statistical analysis
To assess the differences between specifically manipulated cells and the respective controls, statistical analyses using a two-tailed unpaired Student´s t test were performed. P-values < 0.05 were considered significant, those lower than 0.001 were regarded as very significant. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 6 cells is strongly enhanced in the presence of BMSCs. 19 To assess whether this strong ERK1,2 activity was efficiently blocked with siRNAs or by PD98059, we tested both approaches in INA-6 cells cocultured with primary BMSCs. Again, phosphorylation of ERK1 and ERK2 was strongly reduced in both settings ( Figure   2A ). Notably, neither ERK1,2 knockdown, nor treatment with the MEK inhibitor affected the phosphorylation of STAT3 at Tyr705 (Figure 2A ) or at Ser727 (data not shown). Inhibition of the IL-6R/STAT3 pathway with the specific IL-6R antagonist Sant7 (which is derived from IL-6 through seven amino acid changes that endow the polypeptide with a 70 fold higher binding activity at the IL-6R -chain and abolish any agonist activity 23, 24 ) did not affect the phosphorylation of ERK1,2, either in the absence or in the presence of BMSCs (ref. 19 and Figure 2B ). This suggests that in INA-6 MM cells the MAP kinases ERK1,2 are activated mainly by IL-6-independent mechanisms.
Knockdown of STAT3 protein in INA-6 cells
To specifically abrogate signaling through the IL-6R/STAT3 pathway at the level of STAT3, and thus downstream of potential pathway ramifications at the IL-6R, we again used a pSUPER-derived siRNA expression plasmid. The STAT3 siRNA caused strong downregulation of STAT3 protein within two days ( Figure 1C) , and the affected cells were efficiently driven into apoptosis between two and four days after transfection ( Figure 3B ). This result excellently mimicked the effects of IL-6 removal or IL-6R blockade. The specificity of this effect was shown through concomitant transfection of the siRNA expression plasmid and an expression plasmid for a tagged STAT3 protein (pS3R), derived from coding sequence that was rendered unrecognizable for the STAT3 siRNA ( Figure 1C ). This construct was sufficient to prevent the near complete demise of siRNA-transfected cells and rescued them to half the level of control cells or better, as assessed by apoptosis and proliferation assays ( Figures 3E, 4C ).
Combined inhibition of IL-6R/STAT3 and MEK1,2/ERK1,2 signaling is required to induce apoptosis of INA-6 cells in the presence of BMSCs
To assess if BMSC-mediated resistance to apoptosis is connected to the increased levels of activated ERK1,2, we investigated the effects of specific pathway blockade Interestingly, the sensitivity for apoptosis induced by IL-6R-blockade was significantly increased if the cells were additionally treated with PD98059 ( Figure 3D ). The only.
For Western blot analysis of components of the IL-6R/STAT3 and the Ras/MAPK pathway revealed that phosphorylation of ERK1,2, but not of STAT3 (Tyr705), was decreased after treatment with PD98059 ( Figure 5A ). ANBL-6 cells treated with Sant7 displayed a complete lack of phosphorylation of STAT3 (Tyr705). However, the phosphorylation levels of ERK1,2 were only partially decreased by Sant7 ( Figure 5A ), suggesting that also in ANBL-6 these kinases were activated mainly through IL-6R-independent mechanisms.
Treatment of primary MM cells with Sant7 and PD98059 induces apoptosis in the absence and in the presence of BMSCs
To analyze the survival of primary myloma cells after treatment with Sant7 and/or PD98059, we cultured MM cells freshly isolated from bone marrow aspirates of 11 patients with 2 ng/mL IL-6 or in the presence of BMSCs, respectively. The primary only.
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Discussion
We have recently demonstrated that MM cells are protected from apoptosis triggered by blockade of the IL-6R, if they are cocultured with BMSCs. 19 This result suggested that the BM microenvironment supports the activation of signaling pathways, that might substitute for the anti-apoptotic function of IL-6R-mediated STAT3 activation.
We suspected involvement of the MEK1,2/ERK1,2 module, because the strongly enhanced phosphorylation of ERK1,2 in cocultured cells could not be curbed through IL-6R blockade. Activation of this pathway is important for cell proliferation in many experimental systems. This has also been reported in MM, although exclusively in conjunction with IL-6 dependence. 12 It has recently been found that activation of ERK1,2 can mediate survival in some types of cancer. 25, 26 However, it is currently unclear if activation of the MEK1,2/ERK1,2 module has an impact on the survival of MM cells.
In this study, we have employed IL-6-dependent MM cell lines and primary MM cells 28 it is noteworthy that in all cases no effect on the levels of any but the targeted proteins was observed in Western blots. Importantly, the biologic effects from siRNA knockdown in INA For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From rather than Ras mutations contributes to IL-6-independent growth of MM cells.
Treatment of MM cells with the FTI FPTIII was shown to induce apoptosis even in the presence of BMSCs. 19 However, our current data demonstrate that selective elimination of either MEK1,2 or ERK1,2 activity was not sufficient to induce apoptosis of MM cells, excluding a causative role of the MEK1,2/ERK1,2 module for the apoptosis of FTI-treated cells, and underpinning the value of pathway analyses at different levels and with highly selective tools.
A third major signaling system, that has been reported to contribute to the promotion of growth and survival in myeloma cells, is the PI3-kinase/Akt pathway. 36, 37 Blockade of this pathway was shown to curb growth and to induce apoptosis of MM cell lines in vitro, 38 although these effects have yet to be confirmed in the presence of BMSCs.
Furthermore, the Akt homologs represent just one branch of antiapoptotic signaling downstream of PI3K. 39 However, it is tempting to speculate that the combined disruption of different and simultaneously active signaling pathways (e.g. IL-6R/STAT3, MAPK, PI3K/Akt) provides an effective approach for the development of novel and better treatment strategies for MM.
We have recently shown that IL-6-dependent myeloma cells become independent of the IL-6R/STAT3 pathway if they are cocultured with BMSCs. In this paper we present for the first time the biochemical mechanism that mediates this important prosurvival effect. With a combination of genetic and pharmacological approaches, we clearly demonstrate that the strong BMSC-mediated upregulation of the MEK/ERK pathway is achieved mainly in an IL-6-independent manner, and that this is the mechanism through which BMSCs relieve myeloma cells from their requirement for IL-6R/STAT3 signaling. Consequently, combined disruption of both pathways is required to induce apoptosis of myeloma cells in the presence of BMSCs.
Furthermore, these data demonstrate for the first time that the MEK1,2/ERK1,2 module, in addition to its previously-described role in cell proliferation, can critically influence the survival of MM cells. These observations are in good accordance with the lack of an objective clinical response in a phase I study conducted with an anti-IL-6 monoclonal antibody as monotherapy. 40 However, our data underscore that the combined blockade of IL-6R-dependent and -independent signaling pathways could be a promising therapeutic strategy for MM. Table 1 . Statistical analysis revealed significant (*) or very significant differences (**) as indicated. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Table 1 only.
